- Conditions
- Type 2 Diabetes, Type 2 Diabetes Mellitus
- Interventions
- VGo
- Device
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Macon, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Insulin (Humulin® R U-100), Placebo
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- Insulin, Placebo, intranasal nebulizer-like device
- Drug · Other · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Interventions
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina